Gcore Enhances Everywhere Inference With Flexible Deployment Options, Including Cloud, On-Premise, and Hybrid
16.1.2025 10:01:00 CET | Business Wire | Press release
Gcore, the global edge AI, cloud, network, and security solutions provider, today announced a major update to Everywhere Inference, formerly known as Inference at the Edge. This update offers greater flexibility in AI inference deployments, delivering ultra-low latency experiences for AI applications. Everywhere Inference now supports multiple deployment options including on-premise, Gcore's cloud, public clouds, or a hybrid mix of these environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250116487759/en/

Everywhere Inference leverages Gcore’s extensive global network of over 180 points of presence, enabling real-time processing, instant deployment, and seamless performance across the globe (Graphic: Business Wire)
Gcore developed this update to its inference solution to address changing customer needs. With AI inference workloads growing rapidly, Gcore aims to empower businesses with flexible deployment options tailored to their individual requirements. Everywhere Inference leverages Gcore’s extensive global network of over 180 points of presence, enabling real-time processing, instant deployment, and seamless performance across the globe. Businesses can now deploy AI inference workloads across diverse environments while ensuring ultra-low latency by processing workloads closer to end users. It also enhances cost management and simplifies regulatory compliance across regions, offering a comprehensive and adaptable approach to modern AI challenges.
Seva Vayner, Product Director of Edge Cloud and Edge AI at Gcore, commented: “The update to Everywhere Inference marks a significant milestone in our commitment to enhancing the AI inference experience and addressing evolving customer needs. The flexibility and scalability of Everywhere Inference make it an ideal solution for businesses of all sizes, from startups to large enterprises.”
The new update enhances deployment flexibility by introducing smart routing, which automatically directs workloads to the nearest available compute resource. Additionally, Everywhere Inference now offers multi-tenancy for AI workloads, leveraging Gcore’s unique multi-tenancy capabilities to run multiple inference tasks simultaneously on existing infrastructure. This approach optimizes resource utilization for greater efficiency.
These new features address common challenges faced by businesses deploying AI inference. Balancing multiple cloud providers and on-premises systems for operations and compliance can be complex. The introduction of smart routing enables users to direct workloads to their preferred region, helping them stay compliant with local data regulations and industry standards. Data security is another key concern and with Gcore’s new flexible deployment options, businesses can securely isolate sensitive information on-premise, enhancing data protection.
Learn more at https://gcore.com/everywhere-inference.
About Gcore
Gcore is a global edge AI, cloud, network, and security solutions provider. Headquartered in Luxembourg, with a team of 600 operating from ten offices worldwide, Gcore provides solutions to global leaders in numerous industries. Gcore manages its global IT infrastructure across six continents, with one of the best network performances in Europe, Africa, and LATAM due to the average response time of 30 ms worldwide. Gcore’s network consists of 180 points of presence worldwide in reliable Tier IV and Tier III data centers, with a total network capacity exceeding 200 Tbps. Learn more at gcore.com and follow them on LinkedIn, Twitter, and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116487759/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release
Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release
- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release
New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom